OncoCyte Corporation
0KCC.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$208.27M
Close$
Share Statistics
| Market cap | $208.27 Million |
|---|---|
| Enterprise Value | $182.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.65 |
| Beta | 0.51 |
| Outstanding Shares | 34,519,000 |
Return
| Return on Equity | 447.49% |
|---|---|
| Return on Assets | -118.34% |
| Return on Invested Capital | -191.52% |
Valuation & Multiples
| P/E Ratio | -4.48 |
|---|---|
| PEG | 12.55 |
| Price to Sales | - |
| Price to Book Ratio | -5.59 |
| Enterprise Value to Revenue | 93.59 |
| Enterprise Value to EBIT | -3.35 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$462,133
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$437,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.07%▲ 0.07% |
|---|---|
| Total Invested | $179,738 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About OncoCyte Corporation
46 employees
CEO: Mr. Joshua Riggs OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a ...